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Summary
Melanocortin-1 receptor (MC1R) and its ligands, a-melanocyte stimulating hormone (aMSH) and agouti signaling
protein (ASIP), regulate switching between eumelanin and pheomelanin synthesis in melanocytes. Here we
investigated biological effects and signaling pathways of ASIP. Melan-a non agouti (a ⁄a) mouse melanocytes pro-
duce mainly eumelanin, but ASIP combined with phenylthiourea and extra cysteine could induce over 200-fold
increases in the pheomelanin to eumelanin ratio, and a tan-yellow color in pelletted cells. Moreover, ASIP-treated
cells showed reduced proliferation and a melanoblast-like appearance, seen also in melanocyte lines from yellow
(Ay ⁄a and Mc1re ⁄ Mc1re) mice. However ASIP-YY, a C-terminal fragment of ASIP, induced neither biological nor
pigmentary changes. As, like ASIP, ASIP-YY inhibited the cAMP rise induced by aMSH analog NDP-MSH, and
reduced cAMP level without added MSH, the morphological changes and depigmentation seemed independent
of cAMP signaling. Melanocytes genetically null for ASIP mediators attractin or mahogunin (Atrnmg-3J ⁄mg-3J or
Mgrn1md-nc ⁄md-nc) also responded to both ASIP and ASIP-YY in cAMP level, while only ASIP altered their prolifera-
tion and (in part) shape. Thus, ASIP–MC1R signaling includes a cAMP-independent pathway through attractin
and mahogunin, while the known cAMP-dependent component requires neither attractin nor mahogunin.
Significance
Many animal colors and patterns as well as human hair and eye color are genetically determined through
the relative amounts of eumelanin and pheomelanin synthesized. Humans with red (pheomelanic) hair in
general, and with specific hypomorphic MC1R mutations in particular, have increased susceptibility to
melanoma, and the mechanism for this remains uncertain. Melanin, especially pheomelanin, has been
implicated in mutagenesis in melanocytes by ultraviolet light, particularly UVA, via release of reactive
oxygen species that can damage DNA. Ability to regulate the switch between eumelanin and pheomela-
nin synthesis in cultured melanocytes would greatly aid studies of mutagenesis and photocarcinogenesis
in these cells. This work may also shed some light on the longstanding puzzle of how cAMP levels and
ASIP can control both melanocytic differentiation and pigment-type switching.
ª 2009 John Wiley & Sons A/S 623
Pigment Cell Melanoma Res. 22; 623–634 ORIGINAL ARTICLE
Introduction
The diverse patterns of mammalian coat color are
determined by the quantity and distribution of just two
types of organic pigment: eumelanin (black to brown)
and pheomelanin (yellow to red) (Barsh, 2006; Ito,
2003). Both are produced by melanocytes in the hair
bulbs and basal epidermis. They are synthesized and
accumulate in melanosomes, specialized organelles
which are transferred to keratinocytes of the hair and
epidermis (Jimbow et al., 2000). Each melanocyte can
produce either eumelanin or pheomelanin, depending
on the hormonal and chemical environment (Barsh,
2006). In agouti (wild-type) mice the dorsal hairs are
black with a sub-apical yellow band because, in the hair
cycle, follicular melanocytes produce first eumelanin,
then pheomelanin, then eumelanin again (pigment-type
switching) (Barsh, 2006).
Genetic studies of coat color in mice have contributed
greatly to our understanding of the mechanisms of mel-
anin synthesis and its regulation (Bennett and Lamo-
reux, 2003). Two major loci are central to pigment-type
switching in mouse. One is the agouti locus encoding
agouti signal protein (ASIP), with mutants including
non agouti (a, giving a eumelanic black mouse in the
absence of other mutations) and dominant yellow (Ay);
the other is the melanocortin-1 receptor (Mc1r) locus,
formerly extension (e), also with both eumelanic and
pheomelanic mutants (e.g. recessive yellow, Mc1re)
(Barsh, 2006). Melanocortin-1 receptor (MC1R) is a cell-
surface G-protein-coupled receptor for which the best-
known agonist is the soluble peptide aMSH, cleaved
from the precursor pro-opiomelanocortin (POMC) in the
pituitary and skin (Barsh, 2006; Garcı´a-Borro´n et al.,
2005). Binding of aMSH to MC1R is known to activate
adenylate cyclase and cAMP synthesis, promoting
eumelanin synthesis through both post-translational
[review: (Bennett, 1989)] and transcriptional pathways
via microphthalmia-related transcription factor (MITF)
(Bertolotto et al., 1998; Levy et al., 2006). Microphthal-
mia-related transcription factor is a master regulator for
eumelanogenesis, melanocyte differentiation, prolifera-
tion, and survival. It promotes transcription of melano-
cyte-specific gene products including melanosomal
enzymes tyrosinase, TYRP1 and DCT and the matrix
protein SILV ⁄PMEL (Levy et al., 2006). Synthesis of
both eumelanin and pheomelanin starts from tyrosine
oxidation catalyzed by tyrosinase (Ito, 2003). The result-
ing dopaquinone can be a precursor for either eumelanin
synthesis, promoted by TYRP1 and DCT, or pheomela-
nin in the presence of high cysteine concentrations
and ⁄or low tyrosinase activity (Ito, 2003; Land et al.,
2003).
Agouti signaling protein is a soluble protein of 131
amino acids, apparently secreted by dermal papilla
cells in hair bulbs. It competitively antagonizes aMSH
at the MC1R and inhibits the eumelanogenic signal,
downregulating melanogenic enzymes and leading to
pheomelanin synthesis (Barsh, 2006; Millar et al., 1995).
The above account does not however explain certain
data on pigment-type switching. Firstly, a homozygous
null mutation of Pomc has no effect on the black pig-
mentation of a ⁄ a mice (Slominski et al., 2005), and has
also been reported in a black-haired human (Cle´ment
et al., 2008) consistent with reports that MC1R has
constitutive activity (Barsh, 2006; Garcı´a-Borro´n et al.,
2005; Sanchez-Mas et al., 2004). While ASIP requires
the MC1R to affect melanocytes, it can signal in the
absence of added aMSH (Abdel-Malek et al., 2001;
Sakai et al., 1997; Sviderskaya et al., 2001), thus acting
as an inverse agonist at the MC1R rather than just an
MSH antagonist (Barsh, 2006). Secondly, molecules
outside the cAMP pathway are indispensable for ASIP
to signal pheomelanogenesis. Mice with null mutations
at the attractin (Atrn, formerly mahogany) or mahogun-
in (Mgrn1, formerly mahoganoid) loci produce eumela-
nin and no pheomelanin, even in the presence of ASIP
(He et al., 2001, 2003). Attractin is a type I transmem-
brane protein proposed to be an obligatory accessory
receptor for ASIP, while MGRN1 is an E3 ubiquitin
ligase (Barsh, 2006). Although their precise contribu-
tions to ASIP signaling remain unclear, ATRN and
MGRN1 are components with ASIP and MC1R of a
conserved biochemical and genetic pathway (He et al.,
2003). Thirdly, ASIP has not been found to enhance
pheomelanogenesis in cultured melanocytes, although
ASIP can inhibit cAMP generation in MC1R-expressing
cells including melanocytes (Abdel-Malek et al., 2001;
Le Pape et al., 2008; Ollmann et al., 1998). No culture
conditions have been developed in which melanocytes
produce exclusively pheomelanin, even with ASIP. This
suggests that either a factor(s) present in vivo is miss-
ing, or that something present in cultures may prevent
pheomelanogenesis.
To aid understanding of ASIP signaling, we have
sought to develop culture conditions under which ASIP
contributes to overt pheomelanin synthesis by the
melan-a immortal murine melanocyte line. We report
conditions enabling substantially increased pheomela-
nin ⁄eumelanin ratios and visibly yellow cell pellets. To
elucidate ASIP signaling, we also established new
mouse melanocyte lines of four relevant mutant geno-
types, namely Ay mutant cells from mice with constitu-
tive ASIP synthesis from a housekeeping promoter,
Mc1re ⁄ Mc1re cells with a non-functional MC1R recep-
tor, and melanocytes with null mutations of Atrn and
Mgrn1. Taken together, the data demonstrate that ASIP
signaling can reduce melanocyte growth and induce
morphological dedifferentiation as well as affecting
pigmentation. These biological effects are mimicked in
genetically yellow melanocytes without added ASIP, are
incomplete in Atrn- and Mgrn1-null melanocytes, appear
Hida et al.
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independent of cAMP downregulation, and require the
amino terminus of ASIP.
Results
Melanoblast-like morphology and reduced
proliferation of melanocytes grown with ASIP
Melan-a cells (a ⁄ a) grown with 12-O-tetradecanoyl phor-
bol-13-acetate (TPA) normally show a dendritic, well-dif-
ferentiated appearance with abundant eumelanosomes
(Figure 1) (Bennett et al., 1987). The appearance of
these cells was dramatically changed however within
5 days’ culture with 10 nM murine ASIP. The cells
became shorter, smaller, and less dendritic, often with
a crescent shape and ruffled membrane on the convex
side, and markedly less pigmented (Figure 1). This
appearance resembled that of normal and immortal
melanoblasts – unpigmented melanocyte precursors –
in similar media (Figure 1; Sviderskaya et al., 1995).
Melanoblasts are the predominant growing population in
primary neonatal epidermal cultures in our melanocyte
medium in the first 7–10 days, after which they differen-
tiate into melanocytes (Sviderskaya et al., 1995). Agouti
signaling protein was apparently inducing rapid morpho-
logical dedifferentiation of melan-a cells, although a few
cells (possibly non-dividing) remained well-pigmented.
Transitional forms were rare (Figure 1). The proliferation
rate of melan-a cells was also significantly reduced in
the presence of ASIP (data in a later section), as also
reported by Le Pape et al. (2008).
To assess the specificity of these morphological
changes, the effect of ASIP was tested on melan-e2
melanocytes, derived from Mc1re ⁄ Mc1re mice lacking
the normal MC1R. Agouti signaling protein had no
detectable effect on these cells, indicating that the mor-
phological effect is specific (details in a later section).
Pheomelanin ⁄eumelanin ratio markedly enhanced
by ASIP, cysteine, and PTU
Pheomelanin and eumelanin content and their ratio in
melan-a cells were quantitated by chemical degradation
and high performance liquid chromatography. In
preliminary experiments, no increase of pheomelanin
content was detected on growth with ASIP alone, as
previously reported by others. Therefore other relevant
factors, the cysteine concentration and tyrosinase activ-
ity [using the tyrosinase inhibitor phenylthiourea (PTU)],
were modulated together with ASIP addition. Cells were
preincubated with PTU for 2 weeks beforehand to allow
dilution of preexisting eumelanin by cell proliferation
(melan-a cells in the absence of keratinocytes do not
significantly secrete or degrade melanin, as recently
confirmed by Le Pape et al. (2008)), and monitoring only
of melanin synthesized during the experiment. In a typi-
cal experiment, eumelanin content was reduced around
10-fold after growth with 10 nM ASIP for 14 days, while
pheomelanin content was not affected (Figure 2). The
pheomelanin ⁄eumelanin ratio was thus increased over
10-fold. In the presence of ASIP, an additional 2 mM
cysteine reduced eumelanin content further, and
increased pheomelanin content, while continuation of
PTU addition (100 lM) substantially reduced eumelanin
content without significantly affecting pheomelanin (Fig-
ure 2). With ASIP, cysteine, and PTU together pheomel-
anin content was around four times that with ASIP
alone. In the experiment shown, the pheomelanin and
eumelanin ratio in cells grown with ASIP, cysteine, and
PTU was 0.13, over 200-fold higher than with no addi-
tion, and strikingly high compared with other findings
with cultured melanocytes. Cell pellets were brown
rather than black in color (not shown). In a separate
experiment, melan-a cell pellets were prepared after cul-
ture with and without combinations of these factors and
TPA (TPA was previously present throughout). Here
cells were precultured with 500 lM rather than 300 lM
PTU to assist complete depletion of eumelanin, and
grown with ASIP etc for 5 days only. The combination
of ASIP and high cysteine now gave a tan-yellow cell
pellet, or white with continued PTU addition (Figure 2B).
Overlap of the exposure to high PTU with ASIP treat-
ment would have prevented the synthesis of any eumel-
anin in the period before ASIP had taken effect, but
ASIP
mb
C
Figure 1. Morphological and pigmentary changes induced in
melan-a cells by agouti signaling protein (ASIP). Paired phase
contrast (left) and bright-field (right, to show eumelanin) images of
melan-a cells grown in normal growth medium (C, control); or in
the same medium with 10 nM ASIP added for the last 5 days
(ASIP). No phenylthiourea (PTU) or extra cysteine was present (see
text). (mb): normal murine melanoblasts in a primary neonatal
epidermal melanocyte culture, 7 days after explantation, showing
similarity to melan-a cells grown with ASIP. Bar = 100 lm.
Agouti protein signaling in pheomelanogenesis
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reduction of the PTU level was then necessary for any
melanin synthesis at all to occur. Supplementation of
the precursor cysteine was evidently needed for synthe-
sis of enough pheomelanin to give a yellow color. Pel-
lets of cells grown without TPA were darker than those
with TPA, and smaller, reflecting lower cell numbers
(slower growth).
Melanocytes from lethal yellow and recessive
yellow mice: ASIP-like effects on cell morphology
and growth
For comparison with the effects of ASIP and as further
potential pheomelanic melanocytes, we established
three independent immortal melanocyte lines from each
of two genotypes of yellow mice, by crossing an Ink4a-
Arf knockout allele into the strain to prevent cell senes-
cence (Sviderskaya et al., 2002). Lines melan-Ay1 to -3
were grown from Ay ⁄ a mice, in which ASIP is
expressed ubiquitously from a housekeeping promoter,
including in melanocytes, through a genomic rearrange-
ment (Duhl et al., 1994). Lines melan-e1 to -e3 were
obtained from recessive yellow (Mc1re ⁄ Mc1re) mice,
which express a truncated, non-functional MC1R (Rob-
bins et al., 1993). The yellow hair in both genotypes
contains almost exclusively pheomelanin by HPLC analy-
sis (Ozeki et al., 1995).
All lines derived were from Ink4a-Arf) ⁄ ) mice. Melano-
cytes of both yellow genotypes were difficult to grow,
with sparse plating and slow growth in all cultures com-
pared with other genotypes in our experience. Initially
the cells were maintained in standard conditions with
TPA and cholera toxin (CT, 200 pM) to promote proli-
feration. Cultures of a given genotype appeared similar.
The three melan-e cultures appeared hypersensitive to
200 pM CT, with high dendricity, pigmentation and
reduced growth; accordingly CT was varied and stocks
were grown with 20 pM CT (which appeared optimal)
for a number of passages. Cells in all lines of both geno-
types now appeared similar: dark, well-differentiated,
large, flat, bipolar or polygonal cells, usually with numer-
ous visible melanosomes, and similar to melan-a cells
with 20 pM CT (Figure 3). The cell color by light micros-
copy and the pellet color (not shown) were black. For
further studies a single line of each type was used,
melan-Ay1 and melan-e2. Cholera toxin was removed
entirely from both lines after passage 10. Growth
seemed to be transiently inhibited, then recovered. Both
melan-Ay and melan-e cells without CT became small,
curly and bipolar, with few dendrites and little pigment,
again resembling melanoblasts (Figure 3, compare
Figure 1). Melan-Ay cells grew more slowly in growth
medium alone than with 20 pM CT or 100 pM NDP-
MSH [(4-Nle, 7-D-Phe)-a-melanocyte stimulating hor-
mone, a serum-stable synthetic MSH analog] (doubling
times 2.6, 1.6 and 1.5 days respectively, averaged over
three passages with duplicate dishes). Likewise, melan-e
cells showed doubling times of 2.1 and 1.4 days without
and with 20 pM CT. Like melan-a cells with ASIP, some
melan-Ay and melan-e cells without CT remained heavily
pigmented and dendritic. The change was reversible in
both melan-Ay and melan-e cells: when reincubated with
CT, they regained the previous melanocytic appearance
(melan-e: Figure S1; not shown for melan-Ay).
Melan-e cells responded to very low CT concentra-
tions, becoming pigmented and dendritic with as little as
A 
B 
Figure 2. Marked increases in pheomelanin ⁄ eumelanin ratio and
tan coloration by agouti signaling protein (ASIP), cysteine and
phenylthiourea (PTU). Cells were subcultured as needed to prevent
confluency. (A) Eumelanin and pheomelanin content of melan-a
cells after 14 days’ growth with 300 lM PTU followed by 14 days’
growth in standard medium [containing 12-O-tetradecanoyl
phorbol-13-acetate (TPA)] with the indicated additives. Data show
mean ± SEM of three different samples. (ASIP): 10 nM ASIP;
(Cys): 2 mM cysteine plus 100 lM mercaptoethanol; (PTU):
100 lM PTU. (B) Pellets of cells after 14 days’ growth with
500 lM PTU followed by 5 days’ growth with the indicated
additives. (A ⁄C): 10 nM ASIP, 2 mM cysteine and 100 lM
mercaptoethanol; (TPA): 200 nM TPA; (PTU): PTU at 500 lM for
2 days and 100 lM for 3 days. Significances of selected
differences by Student’s t-test (two-tailed) are shown: *P < 0.05;
**P < 0.01; ***P < 0.001, (NS): P > 0.05, not significant.
Hida et al.
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300 fM CT (Figure S1). These conditions were now uti-
lized to test the specificity of the morphological effects of
ASIP. Melan-e cells were grown with or without CT
(300 fM) and with or without ASIP (10 nM). Agouti signal-
ing protein had no detectable effect on melan-e cells
under either set of conditions (Figure S1). Conversely,
melan-a cells with 300 fM CT did respond to ASIP by
switching to melanoblast-like morphology as usual (Fig-
ure S1), confirming that 10 nM ASIP can counteract
300 fM CT in MC1R-positive cells. Together, these find-
ings show that the induction of melanoblast-like morphol-
ogy by ASIP is receptor-mediated and specific.
A carboxy-terminal fragment of ASIP: lack of effect
on cell number, shape or pigmentation of melan-a
cells
To analyze ASIP signaling further, the ASIP C-terminal
analog ASIP-YY was tested. ASIP-YY corresponds to the
cysteine-rich domain, ASIP(80–132), with residues 115
and 124 mutated to tyrosine (Y) to improve protein fold-
ing (McNulty et al., 2005). This domain of ASIP is suffi-
cient for high-affinity receptor binding in vitro. ASIP-YY
displaces NDP-MSH from human melanocortin recep-
tors expressed on HEK-293 human kidney cells, and
inhibits aMSH-stimulated cAMP production, demonstrat-
ing competitive antagonism (McNulty et al., 2005).
Unexpectedly, melan-a cells grown with up to
100 nM ASIP-YY showed no visible difference from con-
trol cells (Figure 4A), and no effect on melanin content
nor cell growth, although 10 nM ASIP induced the usual
shape-change and depigmentation in parallel cultures
(Figure 4B, C). To ensure that our ASIP-YY preparation
retained its known inhibitory activity, we evaluated its
inhibition of MSH-induced cAMP production in melan-a
cells. Cells were stimulated with 30 pM NDP-MSH
(found to give maximal stimulation in this assay – data
not shown), and intracellular cAMP was quantitated by
ELISA. NDP-MSH alone induced a more than 200-fold
increase in cAMP concentration (Figure 5A, black bars).
Neither 1 nM ASIP nor 1 nM ASIP-YY affected this
increase, but 10 nM and 100 nM ASIP reduced it by
2 ⁄3 and to zero respectively (Figure 5A, striped bars).
ASIP-YY did inhibit the cAMP stimulation to a similar
extent (Figure 5A, dotted bars). To exclude the possibil-
ity that ASIP-YY is rapidly degraded in serum-containing
medium, 100 nM ASIP or 100 nM ASIP-YY were incu-
bated with culture medium containing 10% fetal bovine
serum (FBS) at 37C overnight and the mixture was
used as stimulating buffer for cAMP measurements.
Both ASIP and ASIP-YY still inhibited the MSH-induced
cAMP rise completely (Figure 5A, bars with asterisks).
Thus, ASIP-YY could inhibit cAMP stimulation as effec-
tively as ASIP. Lastly, as seen in Figure 5C, melano-
cytes cultured in the absence of added melanocortin
showed similar decreases in cAMP level with either
ASIP or ASIP-YY. This excluded the possibility that the
biological effects were mediated only through an
Figure 3. Melanoblast-like appearance of melan-Ay and melan-e
cells in the absence of CT. Paired phase-contrast (left) and bright-
field (right) images of melan-Ay (Ay) and melan-e (e) cells grown
with 20 pM CT (CT) or for several passages without CT (0). Some
residual eumelanin is seen in some cells of both genotypes without
CT. For reference melan-a cells (a) grown with 20 pM CT are also
shown; there is little difference from melan-a cells without CT
(Figure 1). Bar = 100 lm.
Agouti protein signaling in pheomelanogenesis
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inverse agonist effect of ASIP upon cAMP level, with
the effect not being shared by ASIP-YY.
Atrn and Mgrn1-null melanocytes: partial biological
responses to ASIP but not ASIP-YY
To investigate molecular requirements for the ASIP
effects, immortal melanocytes were isolated carrying
the null mutations Atrnmg-3J (melan-mg1 and -2) and
Mgrn1md-nc (melan-md1 and -2). Attractin specifically
binds the amino-terminal domain of ASIP, apparently
behaving as an accessory receptor for ASIP. Atrnmg-3J
homozygotes are completely resistant to ASIP hair-color
effects in vivo (He et al., 2001). The intracellular E3
ubiquitin ligase mahogunin (MGRN1) also seems crucial:
Mgrn1md-nc homozygous mice likewise lack any pigmen-
tary response to ASIP (He et al., 2003).
These cultures were from Ink4a-Arf+ ⁄ ) animals.
Again, lines of the same genotype appeared indistin-
guishable and are not specified here. Growth from both
mutant genotypes was initially very slow, attributable to
Ink4a-Arf hemizygosity, but lines were eventually estab-
lished. Lines melan-mg2 and -md1 were used for more
detailed studies. Both lines retained slower growth than
melan-a cells (Figure 6), but this was comparable to
growth of the non-mutant cultures from littermate
Ink4a-Arf heterozygous mice of the same strains:
melan-a6 (md control) and melan-a7 (mg control)
showed doubling times of 2.4+ ⁄)0.10 and 1.9+ ⁄)
0.17 days (mean, SEM) respectively. Hence this slow
growth was not due to the pigmentary genotype.
Melan-mg cells grown without CT had a well-differenti-
ated, flat appearance with numerous black melano-
somes (Figure 6, Figure S2). After growth with 10 nM
ASIP, they showed a partial response: a somewhat
melanoblast-like appearance with variable reduction or
clustering of melanosomes (Figure S2), and markedly
slower growth, but 10 nM ASIP-YY gave no detectable
change in shape or growth rate (Figure 6). Melan-md
cells displayed a highly differentiated melanocytic
appearance with long, branching dendrites and heavy
pigmentation in normal medium without CT (Figure 6,
Figure S2). On growth with 10 nM ASIP, there was only
a subtle shape change, with shorter and less-branched
dendrites, a slight crescentic appearance and cells
remaining visibly black-pigmented. However, prolifera-
tion was significantly reduced, whereas 10 nM ASIP-YY
affected neither morphology nor proliferation (Figure 6).
Inhibition of MSH-induced cAMP rise by both ASIP
and ASIP-YY in melan-mg and melan-md cells
cAMP was assayed in melan-mg and melan-md cells
and control melan-a cells after stimulation by NDP-MSH
with or without ASIP or ASIP-YY (Figure 5B). Interest-
ingly, both 100 nM ASIP and 100 nM ASIP-YY com-
pletely inhibited the MSH-induced cAMP rise in both
genotypes, implying that this inhibition requires neither
ATRN nor MGRN1.
Discussion
Here we show that recombinant ASIP induces morpho-
logical dedifferentiation of cultured melanocytes to a
melanoblast-like shape (reduced cell size and dendricity,
acquired crescent shape) and retards growth, as well as
strongly inhibiting eumelanogenesis and greatly increas-
ing the pheomelanin to eumelanin ratio, especially in the
presence of extra cysteine and PTU. The promotion of
pheomelanogenesis by PTU is consistent with the bio-
chemical kinetics favoring cysteinyldopa formation at
low tyrosinase activity (Ito and Wakamatsu, 2008). The
inhibition of melanogenesis and proliferation by ASIP in
melan-a cells were also recently reported by Le Pape
et al. (2008), but genetic requirements, receptor-speci-
ficity and cysteine effects were not analyzed. There
A 
0 ASIP ASIP-YY 
B C 
Control 
Doubling time 
(day) 1.35 1.60 1.37 1.36 
0.006 0.013 0.012 0.001 SE 
10 nM 
ASIP 
10 nM 
ASIP-YY 
100 nM 
ASIP-YY 
Figure 4. Melanoblast-like shape-change, depigmentation and growth inhibition of melan-a cells by agouti signaling protein (ASIP) but not
ASIP-YY. (A) phase-contrast images of melan-a cells grown for 5 days in growth medium (0), with 10 nM ASIP (ASIP) or with 100 nM ASIP-
YY (ASIP-YY). Bar = 100 lm. (B) Total melanin content of melan-a cells grown in growth medium only, or with ASIP or ASIP-YY for 14 days.
Mean and SEM of triplicate dishes. (C) Cell doubling times of melan-a cells subcultured with no addition, ASIP or ASIP-YY for 30 days. Shown
are mean ± SEM of triplicates.
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were some minor differences in outcomes, for example
they saw a reduction in pheomelanin content with ASIP
alone and we did not; these may be attributable to dif-
ferences in protocol (for example our longer treatment
times), in exact culture conditions or in cell passage
level. Le Pape et al. (2009) have also now reported a
valuable microarray analysis of gene expression changes
in melan-a cells grown with ASIP, which supports the
concept of partial dedifferentiation and complements
the present findings; for example reduced expression of
a large number of pigmentary genes including Mitf was
noted after growth with ASIP.
Several observations in the present study indicate
that the morphological dedifferentiation seen with ASIP
is a specific effect rather than due to a contaminant.
Firstly, the cell shape change was deficient in MGRN1-
null melan-md cells and ATRN-null melan-mg cells, and
completely absent from MC1R-null melan-e cells grown
with a trace of CT. Secondly, the altered cells looked
like normal melanoblasts rather than appearing abnormal
or unhealthy. We have never observed any other sub-
stance to transform melan-a cells in this way; on the
other hand ASIP does inhibit forward differentiation of
melanoblasts (Aberdam et al., 1998; Sviderskaya et al.,
2001). Thirdly, the same melanoblast-like shape was
also observed in melan-Ay cells without CT (and without
added ASIP), indicating that it could also be induced by
endogenous mouse ASIP. Again it was seen in melan-e
melanocytes without CT, and it was suppressed in both
melan-Ay and melan-e cells by CT.
Surprisingly, these morphological changes and
reduced melanin content were not provoked by the
ASIP C-terminus (ASIP-YY), although this fully inhibited
the stimulation of cAMP by MSH, and reduced the
cAMP level in the absence of added melanocortin. Thus,
reduced intracellular cAMP is not sufficient for any of
the biological effects of ASIP observed here, even
though many findings support the sufficiency of
increased cAMP for forward melanocytic differentiation
[reviews: (Bennett, 1989; Bertolotto et al., 1998)],
including the effects reported here of CT, a cAMP
agonist.
The growth inhibition by ASIP apparently also required
the N-terminus of ASIP, as it was not produced by
ASIP-YY. However it required neither MGRN1 nor
ATRN, as melan-md and -mg cells were also inhibited, if
anything more markedly than melan-a cells. This was
the only tested biological effect of ASIP not diminished
in melan-mg and -md cells. Surprisingly, it appeared
independent of the ability to reduce cAMP level, as
ASIP-YY affected cAMP but not growth. We cannot
entirely discount the possibility that this growth inhibi-
tion was partly non-specific, but a counterargument is
that slower growth than in wild-type melanocytes also
accompanied the melanoblast-like phenotype seen in
melan-Ay cells which make endogenous ASIP, and
melan-e cells without CT.
Figure 5. (A) Inhibition of NDP-MSH-induced cAMP rise by both
agouti signaling protein (ASIP) and ASIP-YY in melan-a cells.
Intracellular cAMP per well was measured in cultures that had
been plated and allowed to attach overnight, after stimulation for
30 min with 30 pM NDP-MSH (M), with or without ASIP (A) or
ASIP-YY (Y). Figures in parentheses are concentration of ASIP or
ASIP-YY in nM. *RPMI1640 medium with 10% FBS was incubated
with ASIP or ASIP-YY at 37C overnight and was used as
stimulating buffer, followed by application of NDP-MSH. Shown are
mean ± SEM of triplicate wells. (B) Inhibition of NDP-MSH-induced
cAMP rise by both ASIP and ASIP-YY in melan-mg and melan-md
cells. Assay as above, using 100 nM ASIP (A) or 100 nM ASIP-YY
(Y). The reason for the lower apparent stimulation of melan-a cells
by NDP-MSH in (B) than in (A) is unknown; it may reflect change in
the assay reagents with time. However the relative responses of
different genotypes are clear. (C) Reduction of basal cAMP by both
ASIP and ASIP-YY. In this experiment only, to increase assay
sensitivity, melan-a cells were plated at a higher number of 6 · 104
cells ⁄well, preincubation with isobutylmethylxanthine (IBMX) was
for 5 h at 1 lM, and incubation with the stated additives was for
5 h. IBMX alone (1 lM, a low concentration) had no significant
effect, whereas both ASIP (A) and ASIP-YY (Y) at 10 nM gave
significant reductions in cAMP levels compared with 1 lM IBMX
alone (P = 0.013, P = 0.003 respectively). Similar effects were
seen under slightly varied conditions (not shown).
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Melanocortin receptors and ATRN are the only mole-
cules known to bind ASIP (Abdel-Malek et al., 2001; He
et al., 2003). Attractin is required for ASIP effects in the
mouse, and was suggested to function to enhance
ASIP–MC1R binding (Barsh, 2006). Thus it was surpris-
ing that we saw partial morphological and depigmenta-
tion effects of ASIP on ATRN-null melanocytes. Perhaps
ASIP also has some partial effects in vivo in ATRN-null
mice, but they are not sufficient to dilute visibly the
black color of hair. Agouti signaling protein (ASIP)’s mor-
phological effects were very deficient in MGRN1-null
melanocytes, consistent with the requirement of
MGRN1 for ASIP action in mice.
Through which signaling pathway does ASIP ⁄MC1R
induce biological effects, if not through reduced cAMP?
Each of five melanocortin receptor subtypes couples to
adenylate cyclase, generating cAMP and activating PKA
(Garcı´a-Borro´n et al., 2005). Other signaling intermedi-
ates reported to be activated by MSH ⁄MC1R in melano-
cytes or melanoma cells include protein kinase C, nitric
oxide, p38MAPK and p42 ⁄p44MAPK, with the first
three reported to stimulate melanogenesis ⁄differentia-
tion, but in each case there was evidence that the
effect was dependent on cAMP signaling (Buffey et al.,
1992; Englaro et al., 1995; Park et al., 2006; Smalley
and Eisen, 2000; Tsatmali et al., 2000). Another candi-
date pathway is through Gq and ⁄or phospholipase C.
Coupling to inositol triphosphate (IP3) and Ca
2+signaling
(which Gq and phospholipase C could mediate) has been
reported for a number of human and mouse melanocor-
tin receptors, including MC1R (Eves et al., 2003; Garcı´a-
Borro´n et al., 2005; Mountjoy et al., 2001). Recently, a
novel high-affinity ligand for MC1R was identified in
dogs, namely canine b-defensin 103 (CBD103), encoded
at the K locus (Candille et al., 2007). Transgenic mice
expressing cDNAs for either of two (canine) CBD103
alleles on an A ⁄A (agouti) background had a black coat
color. Canine and human b-defensins could bind dog,
mouse and human MC1Rs, but not ASIP-YY. Interest-
ingly, neither canine cDNA affected cAMP concentration
in melan-a melanocytes. CBD103 might act by com-
petitively inhibiting ASIP binding, or might elicit cAMP-
independent signaling from the MC1R to promote
eumelanogenesis (Candille et al., 2007).
Considering this with our results, we hypothesize dual
signaling from MC1R, as follows (Figure 7). Melano-
cortin-1 receptor can activate both cAMP and another
signaling pathway X. Activation of X may be cAMP-
dependent or -independent; X may also be the
cAMP-independent pathway activated by b-defensins.
Agouti signaling protein can antagonize cAMP signaling
through its C-terminus (as in ASIP-YY) and independently
antagonize X signaling through its N-terminus and
through ATRN and MGRN1, resulting in inhibition of
eumelanogenesis, enhancement of pheomelanogenesis
(under suitable conditions), and melanoblast-like mor-
phology. To explain the activation of eumelanogenesis
by cAMP, yet persistence of eumelanogenesis when
the cAMP signal is withdrawn, we suggest a positive
feedback loop (Figure 7), likely to involve MITF as MITF
mediates melanocytic differentiation. Agouti signaling
protein can also downregulate MITF gene expression
B C 
A 
mg 
0 
mg 
ASIP 
mg 
YY 
md 
0 
md 
ASIP 
md 
YY 
Control 
Melan-md Melan-mg
Doubling time 
(day) 2.54 4.38 2.60 
0.034 0.206 0.054 SE 
10 nM 
ASIP 
10 nM 
ASIP-YY Control 
Doubling time 
(day) 1.88 4.77 1.84 
0.005 0.134 0.012 SE 
10 nM 
ASIP 
10 nM 
ASIP-YY 
Figure 6. Melanoblastic shape-change and growth inhibition of melan-mg and melan-md cells by agouti signaling protein (ASIP) but not ASIP-
YY. Melan-mg cells (mg) and melan-md cells (md) were incubated for 5 days in growth medium alone (0), with 10 nM ASIP (ASIP) or with
10 nM ASIP-YY (YY). Bar = 100 lm. No Cys or phenylthiourea (PTU) present. Cell doubling times of melan-mg cells (B) and melan-md cells
(C) were measured in the presence of 10 nM ASIP or 10 nM ASIP-YY for 30 days. Shown are mean ± SEM of triplicate cultures. Retardation
of proliferation by ASIP was highly significant for both genotypes by Student’s t-test (P < 0.001), while ASIP-YY had no significant effect.
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(Le Pape et al., 2009). The components of this proposed
loop remain to be elucidated, but we suggest that
MGRN1, a ubiquitin ligase, may break the loop by ubiq-
uitinating and destabilizing one component Y. This
would lead to a less-differentiated state with low MITF
activity, permissive for pheomelanogenesis.
Full pigment type-switching to give predominantly
pheomelanin and a clear yellow color has not been
achieved in cultured melanocytes or melanoma cells
treated with ASIP (Graham et al., 1997; Sakai et al.,
1997), or ASIP and PTU (Le Pape et al., 2008). Likewise,
pheomelanin content in melan-a cells was not increased
by ASIP alone in this study. With ASIP, cysteine and
PTU however, a substantially increased pheomela-
nin ⁄eumelanin ratio of 0.13 was seen here, although
this was not complete pigment type-switching, as the
ratio in yellow mouse hair can exceed 100:1 (Ozeki
et al., 1995). Moreover, visibly yellow pelletted cells
were obtained with a specific combination of intensive
PTU pretreatment, ASIP and cysteine, illustrating the
sensitivity of the pheomelanin–eumelanin ratio to pre-
cise culture history. Further work is needed to produce
overt pigment-type switching in culture, but further
combinations of the above factors may prove fruitful.
Receptor-specific induction of a melanoblast-like
shape from melanocytes by ASIP and a similar effect of
MC1R inactivity have not been reported before. The
recurrent melanoblast-like morphology in genetically yel-
low and ASIP-treated melanocytes suggests a possible
relationship between dedifferentiation and pheomelano-
genesis, supported by the known inhibition of forward
melanoblast differentiation by ASIP. Mc1re ⁄Mc1re mela-
nocyte cultures were reported previously, but were
grown with dibutyryl cAMP and were described only as
pigmented (Costin et al., 2004). Melan-a cells treated
with ASIP lose expression of TYRP1, DCT, and SILV ⁄
PMEL, all needed to generate normal eumelanosomes
but not pheomelanosomes, while retaining low tyrosi-
nase expression (Sakai et al., 1997) which would favor
pheomelanogenesis (Ito, 2003). Thus a partial equiva-
lence between melanoblasts and the cells that make
pheomelanin seems possible; melanoblasts do express
some tyrosinase (Sviderskaya et al., 1995), have low
DCT, TYRP1, and MITF (Aberdam et al., 1998), and con-
tain premelanosomes (Hirobe and Takeuchi, 1978).
Premelanosomes and pheomelanosomes are evidently
not the same, as the latter contain pheomelanin, but
the difference may depend on relatively minor factors
such as cysteine concentration.
Taken together, our results indicate that ASIP’s
biological effects require a cAMP-independent signaling
pathway via MC1R and MGRN1 and facilitated by
ATRN, which plays a key role in regulating melanogene-
sis and melanocyte morphology.
Materials and methods
Reagents
Tissue culture plastics and FBS were from Gibco Europe (Paisley,
UK). Cholera toxin, TPA, PTU (also known as phenylthiocarbamide),
NDP-MSH and 3-isobutyl-1-methylxanthine (IBMX) were from
Sigma Chemical Co. (Poole, UK). Full length recombinant mouse
ASIP was generated using a baculovirus expression system; mate-
rial used for these studies was purified by cation and anion
exchange chromatography as previously described (Ollmann et al.,
1998), and was >99% pure. ASIP-YY was synthesized as described
(McNulty et al., 2005), was 90–95% pure and has MC1R binding
activity equivalent to that of normal ASIP (McNulty et al., 2005). All
protein factor stock solutions were prepared in Dulbecco’s phos-
phate-buffered saline (PBS) lacking CaCl2 and MgCl2, with bovine
serum albumin (1 mg ⁄ml) as carrier, and stored at )70C. For all
experiments involving cysteine addition to culture medium, 100 lM
mercaptoethanol was added to enhance cysteine stability.
Establishment of immortal murine melanocyte lines
Mice were of the C57BL ⁄ 6J inbred strain and a ⁄ a at the agouti ⁄A-
SIP locus unless otherwise stated. All experiments complied with
local and European legislation concerning vivisection and the experi-
mentation and use of animals for research purposes. Mice with
color mutations were crossed to mice carrying an Ink4a-Arf deletion
allele for one or more generations, to give Ink4a-Arf) ⁄ ) or + ⁄ ) off-
spring that yield diploid melanocytes deficient in cell senescence
and readily established in culture (Sviderskaya et al., 2002). For
melan-Ay-1 to -3, Ay ⁄ a, Ink4a-Arf) ⁄ ) mice were generated from
Ay ⁄ a mice kindly provided by FR Gruijl, Leiden University Medical
Center, the Netherlands. A dermal fibroblast line of this genotype,
fibro-Ay, was also isolated as a potential source of secreted ASIP;
not characterized further. For melan-e1 to -e3,Mc1re ⁄ e, Ink4a-Arf ) ⁄ )
mice were used. For melan-mg1 and -mg2 (Atrn null) and
Figure 7. Model to account for responsiveness to cAMP level in
activation but not inactivation of eumelanin synthesis. See
Discussion for main explanation. (A-YY) ASIP-YY, (Mc) melanocyte,
(Mb) melanoblast, (Ub) ubiquitinylation. Melanocortin-1 receptor
(MC1R) is shown with some basal activity (left, lost in e mutant),
to explain why POMC null, a ⁄ a mice are black, and related data
(see text). (This might alternatively be due to BD103 or some
unknown signal). Agouti signaling protein (ASIP) would not be
required for pheomelanogenesis unless Y has been switched on
by the MC1R ⁄ cAMP pathway, hence inactive MC1R would give
a yellow color even with deficient MGRN1, as seen in e ⁄ e,
md ⁄md mice.
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melan-md1 and -md2 (Mgrn1 null), Atrnmg-3J ⁄mg-3J, Ink4a-Arf + ⁄ )
mice on a C3H a ⁄ a background and Mgrn1md-nc ⁄md-nc, Ink4a-Arf + ⁄ )
mice on a mixed a ⁄ a strain background were generated (inbred not
available). Neonatal mouse skins were sent to London in chilled cul-
ture medium, and used to isolate epidermal melanocytes with the
aid of immortal keratinocyte feeder cells as described (Sviderskaya
et al., 1997, 2002), using RPMI1640 medium (Sigma) containing
10% FBS, 200 nM TPA, and 200 pM CT, gassed with CO2 (10%
v ⁄ v). Routine subculture was as described (Sviderskaya et al.,
1997). Littermate wild-type lines were also established as potential
strain controls (melan-a5 and -a6 from the Mgrn1md-nc stock and
melan-a7 from the Atrnmg-3J stock); these resembled other black
melanocyte lines. After passage 10, CT was removed from all cell
lines without cessation of proliferation. Melan-a cells (Bennett
et al., 1987) were grown in the same medium (no CT). Melan-a
cells are functionally Ink4a-Arf null, expressing neither p16INK4A nor
ARF proteins (Sviderskaya et al., 2002).
Melanin and cell proliferation assays
Lyophilized samples of 0.5–1.0 · 106 melanocytes were processed
for chemical analyses to detect the specific degradation product of
eumelanin, pyrrole-2,3,5-tricarboxylic acid (PTCA), after perman-
ganate oxidation (Ito and Fujita, 1985; Ito and Wakamatsu, 1994)
and the specific degradation product of pheomelanin, 4-amino-3-
hydroxyphenylalanine (4-AHP), after hydriodic acid hydrolysis (Ito
and Fujita, 1985; Wakamatsu et al., 2002). Both products were
quantified by HPLC. The amounts of eumelanin and pheomelanin
were obtained by multiplying the amounts of PTCA and 4-AHP by
conversion factors of 50 and nine respectively. For measurement
of total melanin (Friedmann et al., 1990), cell pellets were resus-
pended in 100 ll NaOH (1 M) and diluted with 400 ll water. The
OD472 was measured and converted to melanin content via a stan-
dard curve using synthetic melanin (Sigma). This was normalized to
cell number.
To calculate cell doubling times, triplicate cultures were plated
at the specified density on 3-cm dishes. When cells were nearly
confluent, they were detached with trypsin-EDTA, counted in
triplicate by hemocytometer, and replated at a recorded density.
A growth curve was drawn from the relative population increase.
Cell doubling time over 30 days’ growth was calculated from the
curve.
cAMP assays
Cellular cAMP concentrations were measured using the HitHun-
terTM cAMP assay kit (Amersham Biosciences, UK), according to
the manufacturer’s instructions with slight modifications. Cells
were plated into 96-well plates at 2 · 104 cells ⁄well, 100 ll med-
ium ⁄well and incubated at 37C in normal culture conditions over-
night. Medium was gently aspirated. Then, unless specified, cells
were incubated in serum-free RPMI1640 with BSA (1 mg ⁄ml) and
0, 10 or 100 nM ASIP at 37C in a humidified atmosphere of 10%
CO2 for 30 min. To assess the effect of incubation of ASIP in med-
ium, RPMI1640 containing 10% FBS and 100 nM ASIP was incu-
bated under the same conditions for 12 h and this medium was
applied in place of the medium with fresh ASIP. For cell stimula-
tion, NDP-MSH (30 pM) and IBMX (1 mM) were added directly to
the ASIP-containing medium and cells were incubated at 37C for
30 min. The cells were lysed and processed according to the man-
ufacturer’s protocol. One hour after the last reaction step, the lumi-
nescence of each well was measured with a SynergyTM HT Multi-
Mode microplate reader equipped with KC4 for Windows data-
reduction software (Bio-Tek Instruments, VT, USA). The cAMP con-
centration in each sample was calculated by comparing relative
luminescence of the sample with that of a cAMP standard.
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